Comparison

用药助手 vs MCDEX移动版

Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.

Head to head
About

用药助手

This clinical decision support tool provides medical professionals with comprehensive drug information, disease treatment guidelines, and practical medical tools. It aims to assist in making more standardized and safer clinical decisions based on authoritative data and expert input.

Highlights
  • Comprehensive drug information
  • Clinical decision support for diseases
  • Access to authoritative guidelines
  • Practical medical tools
  • Expert-reviewed data
  • Real-time updates
Features
Read full description

用药助手隶属于丁香园旗下,是为医药人士定制的「临床决策助手」,致力于辅助医药专业人员做出更规范、更安全的临床决策。 用药助手覆盖药品、疾病、指南、医学工具四大模块,数据来源于国内外权威文献、指南等,并邀请国内三甲医院医生参与数据生产生与审核,为专业医生提供靠谱的诊疗决策服务。 【应用特点】 300万+专业用户都在使用 1. 权威靠谱:甄选行业权威数据,收录全面、更新迅速; 2. 内容实用:一线临床医生参与研发,为中国医生量身打造; 3. 简单易用:海量信息化繁为简,支持随时随地快速查阅。 【核心服务介绍】 1. 药品信息:支持免费查询超 70000 份国内外上市药品说明书,覆盖国内 99% 的药品数据,并根据药监局药品信息实时更新。同时,包含 2000+ 药物成分(ATC 分类)的合理用药指导,包括用法用量(含国内外用法用量对比)、安全用药(含特殊人群用药调整、妊娠哺乳用药安全、药物警戒等)、药理毒理、患者教育等最受医生关注的用药知识。 2. 临床决策:4000+ 条临床常见疾病的诊疗决策支持,覆盖 90% 临床常见疾病。内容涵盖基础知识、诊断依据、治疗原则、控制目标等核心诊疗环节,并提供疾病的「药物治疗」信息查询,内容更实用,决策更安全。 3. 临床指南:收录 30000+ 国内外权威机构发布的指南、专家共识,支持快速检索、在线查看,以及 PDF 分享或下载。 4. 实用工具:包含肿瘤分期、相互作用、配伍禁忌、医学计算公式(800+)、临床路径、抗菌谱查询等,临床决策更高效。 【自动续费服务声明】 1. 订阅价格(以app内最新情况为准):连续包月 45 元/月、连续包年 348 元/年; 2. 付款:用户确认购买并付费后计入 iTunes 账户; 3. 自动续订:苹果 iTunes 账户会在到期前 24 小时内扣费,扣费成功后订阅按订阅周期顺延; 4. 取消续订:如需取消续订,请在当前订阅周期结束至少 24 小时以前,手动在 iTunes/Apple ID 设置中关闭自动续费功能;若在到期前 24 小时内取消,将收取订阅费用; 会员续费协议 https://3g.dxy.cn/newh5/view/rule/drugs_auto_renewal 用户协议 https://3g.dxy.cn/newh5/view/rule/drugs_userAgreement 隐私政策 https://3g.dxy.cn/newh5/view/rule/privacyPolicy_drugs 【免责声明】 丁香园用药助手(下称“平台”)致力于为临床医生提供相对及时全面的疾病、药品、指南等信息以辅助临床决策。 平台涉及的医学信息内容广泛,但这些内容不包含所有适当的诊疗护理方法,也未排除合理运用可获得相同治疗结果的诊疗、护理方法,亦不视为平台提供了任何医疗建议、诊断或治疗方法。关于任何特定诊疗程序的适当性,必须由医生根据患者个体表现出的所有情况做出最终判断。平台对于任何用户因使用或参考本平台内容而做出的任何判断或决定以及该等判断或决定直接或间接导致的任何后果不承担任何责任。 平台提供的部分内容源自互联网的资料信息或一些非规范性文件,初衷和目的是用于学术交流与讨论、补充临床诊疗过程中的信息及注意事项,并不意味着平台对前述内容有任何主观的认可或推荐。如果您认为我们的转载侵犯了您的权益,请与我们联系(联系邮箱:lawyer@dxy.cn),我们将在核实后5个工作日内予以删除处理。 平台会尽可能及时的、全面的收集展示最新的疾病、药品、指南等信息,但医药科学知识不断更新,其涵盖的信息也不断变化,可能导致部分信息缺失或滞后,我们无法保障平台提供的全部信息为当前最新最及时信息,请您谅解,也欢迎您向平台反馈、纠正平台上滞后、错误的信息,提出您宝贵的意见。

About

MCDEX移动版

This mobile application provides a comprehensive database for clinical rational drug use information. It integrates authoritative domestic and international medical information sources, offering details on drug monographs, pregnancy/lactation use, and drug interactions for healthcare professionals.

Highlights
  • Clinical rational drug use information
  • Integrated domestic and international medical sources
  • Drug monographs
  • Pregnancy and lactation drug information
  • Drug interaction data
  • Database query software
Features
Read full description

合理用药信息支持系统移动版(简称MCDEX移动版)是根据临床合理用药专业工作对临床信息的需要,开发的一个集成了国内外权威医药信息源的数据库查询软件系统。系统收载了临床用药所需的信息,如药物专论、妊娠哺乳用药、药品说明书、药物相互作用等,是医师、药师等医疗卫生技术人员获取医药信息的有效工具。 咨询电话:028-85183848。

Screenshots

用药助手4 screens
MCDEX移动版4 screens

Verdict

The call

The clearest difference is rating: 用药助手 at 4.8 against MCDEX移动版's 4.0. 用药助手 also leads on ratings volume (81 vs 1) and update cadence (every 9 days vs every 6 weeks). MCDEX移动版's advantage is in-app purchases (none vs 18) and iOS requirement (13 vs 15.0). On price, ads and device support there is nothing between them.

Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS

CostPrice · In-app purchases · Ads · Monetization

Both are free to download. 用药助手 sells 13 in-app purchases, starting at $2.99 per month. MCDEX移动版 asks for nothing beyond the download.

ReceptionRating · Positive reviews · Number of ratings

用药助手 holds the better App Store score, 4.8 against 4.0. That said, the two scores are not equally well evidenced: 用药助手 has 81 ratings behind it against 1, so its average is the more settled of the two.

UpkeepUpdate frequency

用药助手 ships an update every 9 days, MCDEX移动版 every 6 weeks. The most recent releases landed on October 24, 2026 and October 17, 2026 respectively.

Scorecard6 real differences · 4 level
用药助手 versus MCDEX移动版: the parameters behind the verdict, then further details
Parameter用药助手MCDEX移动版
PriceFreeFree
Rating4.8 (81 ratings) — better4.0 (1 ratings)
Positive reviews84.0% of reviews—
Number of ratings81 — better1
Update frequencyEvery 9 days — betterEvery 6 weeks
AdsNoNo
In-app purchasesYesNo — better
MonetizationFree with in-app purchasesFree — better
DevicesiPhone, iPad, iPod — betteriPhone, iPod
Requires iOS15.013 — better
Further details — not scored
Size102 MB2 MB
Age rating17+17+
DeveloperGuanlan Networks (Hangzhou) Co. Ltd.Sichuan Medicom Software Co.,Ltd.

Customer experience

用药助手

All ratings81 ratings
Positive96.3%
Neutral0.0%
Negative3.7%
Written reviews50 reviews
Positive84.0%
Neutral2.0%
Negative14.0%

MCDEX移动版

All ratings1 ratings
Positive100.0%
Neutral0.0%
Negative0.0%

In-app purchases

13 purchases

用药助手

Subscriptions8
  • 专业版会员连续包月$2.991 Month
  • 专业版PLUS会员连续包月2 variants$3.991 Month
  • 1个月会员连续订阅1 Month trial$5.991 Month
Show 5 more
  • 专业版会员连续包年$24.991 Year
  • 专业版PLUS会员连续包年3 variants$34.991 Year
  • 1年会员连续订阅$49.991 Year
  • 1年会员连续订阅(认证用户专享)1 Year trial$49.991 Year
  • 1年会员连续订阅(老用户专享)1 Year trial$49.991 Year
One-time5
  • 专业版PLUS 1个月会员$9.99
  • 延长1年专业版会员(优惠)$14.99
  • 专业版PLUS 1年会员(教育版)$19.99
Show 2 more
  • 延长1年专业版会员$29.99
  • 专业版PLUS 1 年会员$59.99
None

MCDEX移动版

No in-app purchases

Questions

Is 用药助手 free?
用药助手 is free to download, with in-app purchases available.
Is MCDEX移动版 free?
MCDEX移动版 is free to download, with no in-app purchases.
Which has better reviews, 用药助手 or MCDEX移动版?
用药助手 is rated higher. 用药助手 averages 4.8 out of 5 from 81 ratings, while MCDEX移动版 averages 4.0 from 1 ratings.
Do 用药助手 or MCDEX移动版 have ads?
Neither 用药助手 nor MCDEX移动版 shows ads.
Which is updated more often, 用药助手 or MCDEX移动版?
用药助手 ships an update every 9 days, and MCDEX移动版 every 6 weeks. Most recently, 用药助手 was updated on October 24, 2026 and MCDEX移动版 on October 17, 2026.

Other comparisons